3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Active not recruiting
1
Sponsor Class
NETWORK
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Conditions
Breast Neoplasms
5
Prostatic Neoplasms
3
Melanoma
2
Urinary Bladder Neoplasms
1
Spondylitis, Ankylosing
1
Skin Carcinoma
1
Signs and Symptoms
1
Rectal Neoplasms
1
Psoriasis
1
Pancreatic Neoplasms
1
Overweight
1
Ovarian Neoplasms
1
Obesity-Related Malignant Neoplasm
1
Obesity
1
Neoplasms
1
Neoplasm Metastasis
1
Motor Activity
1
Malignant Solid Neoplasm
1
Malignant Female Reproductive System Neoplasm
1
Lymphedema
1
Lupus Erythematosus, Systemic
1
Kidney Neoplasms
1
Inflammatory Bowel Diseases
1
Hematopoietic and Lymphatic System Neoplasm
1
Hematologic Neoplasms
1
Endometrial Neoplasms
1
Crohn Disease
1
Colorectal Neoplasms
1
Colonic Neoplasms
1
Colitis, Ulcerative
1
Interventions
Cyclophosphamide
7
Specimen Handling
5
trametinib
3
fludarabine
3
Tacrolimus
3
Standard of Care
3
Mycophenolic Acid
3
Magnetic Resonance Spectroscopy
3
GSK2636771
3
Biopsy
3
venetoclax
2
talquetamab
2
ruxolitinib
2
fludarabine phosphate
2
dabrafenib
2
capivasertib
2
binimetinib
2
adavosertib
2
Whole-Body Irradiation
2
Practice Guidelines as Topic
2
Nivolumab
2
Crizotinib
2
Ado-Trastuzumab Emtansine
2
2-(3-(2-(1-isopropyl-3-methyl-1H-1,2-4-triazol-5-yl)-5,6-dihydrobenzo(f)imidazo(1,2-d)(1,4)oxazepin-9-yl)-1H-pyrazol-1-yl)-2-methylpropanamide
2
ulixertinib
1
trastuzumab biosimilar HLX02
1
sapanisertib
1
relatlimab
1
rasburicase
1
plerixafor
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Hematologic Neoplasms
×
Methods
×
30 days
×
Clear all
NCT04960787
2026-05-14
CREDIT
SWOG Cancer Research Network
Phase NA
Active not recruiting
331 enrolled